Angiotensin-1-7 Diagnostic Method for Respiratory Disease Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The complexity of measuring Angiotensin (1-7) levels and the variability in patient populations and measurement methods make it challenging to predict clinical complications in patients with viral respiratory diseases like SARS-CoV-2, and existing methods do not allow for a simple binary diagnostic.
Innovation Solution
A method involving the measurement of Angiotensin (1-7) levels, along with other biomarkers such as CRP, TGFβ, LDH, and ferritin, from a blood sample at admission, and comparing these levels to those of patients with favorable and poor outcomes to predict the risk of clinical complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple biomarkers (Ang-(1-7), CRP, TGFβ, LDH, ferritin) are measured to improve prediction accuracy, then the reliability of clinical complication prediction is improved, but the device complexity and measurement difficulty increase
Solution Approach 1:
The patent segments the complex diagnostic process into multiple independent biomarker measurements (Ang-(1-7), CRP, TGFβ, LDH, ferritin), each measured separately using standardized assays. This segmentation allows each parameter to be evaluated independently while collectively providing comprehensive prediction accuracy for clinical complications.
Solution Approach 2:
The patent employs a multi-functional diagnostic approach where a single blood sample is used to measure multiple biomarkers simultaneously. This universal sampling method simplifies the overall process while maintaining high reliability, as one blood draw provides information across multiple pathological dimensions (inflammation, fibrosis, organ function).
2Ease of operation
If Ang-(1-7) levels are measured using ELISA method, then the ease of operation is improved, but the measurement precision deteriorates due to inability to discriminate between Angiotensin 2 and Ang-(1-7)
Solution Approach 1:
The patent uses specific antibodies as intermediaries in ELISA assays that are designed to distinguish between Ang-(1-7) and Angiotensin II. These antibodies act as mediators that bind selectively to target peptides, enabling discrimination despite the structural similarity between the two angiotensin forms.
Solution Approach 2:
The patent employs parameter changes in the ELISA methodology, including optimization of incubation times, antibody concentrations, and washing steps, to enhance the discrimination capability between Ang-(1-7) and Angiotensin II while maintaining the operational simplicity of the ELISA format.
Data Source
AI summary
A diagnostic based on Angiotensin 1-7 level, possibly in synergy with other blood parameters, to predict the outcome of infected patients by respiratory viral diseases and the corresponding drugs to prevent worsening of the disease for the patients predicted to be at higher risk.